A Phase 0/II Study of Ceritinib (LDK378) in Preoperative Glioblastoma Multiforme (GBM) and CNS Metastasis Patients Scheduled for Resection to Evaluate Central Nervous System (CNS) Penetration
Phase of Trial: Phase 0
Latest Information Update: 16 Dec 2016
At a glance
- Drugs Ceritinib (Primary)
- Indications Brain metastases; Glioblastoma
- Focus Pharmacokinetics
- 10 Jun 2017 Biomarkers information updated
- 12 Dec 2016 Planned primary completion date changed from 1 Nov 2016 to 1 Jun 2017.
- 24 May 2016 Status changed from not yet recruiting to recruiting.